Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks very much for your preliminary investigation. It seems that a 1-year clock is ticking from date of liquidation, in which the liquidator must divest of company assets and reimburse
shareholders their due. I believe that Kempers is the named liquidator…the same individual who orchestrated the massive reverse split of our shares last fall.
I have been looking everywhere for the final report of the 5-year NIH-funded HIV study that MYMX was involved in…no luck finding that yet. I do believe that a monetary accounting of the liquidation could be substantial given all the research, patents, etc. that MYMX was involved in over several decades. Worth pursuing? If so, I concur that we would need to work with a Swiss attorney if enough are willing to pursue this. Hopefully your message will get a response soon.
Can we get a head count on how many investors are interested in pursuing this?
It seems we only have until May 19 to file claims with MYMX. If anything is in the works please post so others can join/support the effort. I did try to track down the final report of the 5 year NIH-funded grant, but have not yet seen it. Does anyone have
access to a report of findings that Dr. Ruth Ruprecht may have published this month? Haven’t found that either.
I just spent 24 hours trying to get access to official documents related to the MYMETICS SA liquidation process and how we creditors can file claims. It has been hard, as all documents/publications are in French. I requested that the publishing journal send a version in English (which their web site says they do), but they responded negatively. I don’t speak or read French, but perhaps others here do.
Relevant documents are published in the Swiss Official Gazette of Commerce (SOGC), file #CHE-113.618.351. What I gleaned from this is the following:
New Address: Mymetics SA
Route de la Corniche 4
1066 EpalingesSwitzerland
There was a change of exec officers /reps on 1/3, 2024
SOGC daily register #86 SOGC publ #1005928290
another change of exec officers/reps on 1/31/2024
SOGC daily register #2447 SOGC publ #1005952896
liquidation and change of exec officers/reps on 4/10 2024
SOGC daily register #7598 SOGC publ #1006009160
I believe claims must be filed by by May 19, 2024. How do we do that? Will appreciate any help regarding this.
I agree. How can we pursue getting proper information on the liquidation and investor remuneration? Seems there is only a brief window of 2 weeks or so to submit a claim?
Yes, this is all good. Delfin is following up to ensure that all legal permits be renewed prior to expiring…I believe this is the last one that must be renewed by end of June. Staying on top of it, lining up final approvals to clear the way for FID.
Thanks for posting that, AhsokaXC. A small group of us public shareholders left … we remain in patient waiting mode. It’s very hard to believe that MYMX is not “in the running” for some kind of merger/buyout. Their portfolio and patents are just way too valuable to throw away. Haven’t seen any selling by insiders, and they know far more than we do.
As Siar notes, the HIV study results next month may prove a catalyst to MYMX news.
So today is the day MYMX shut down as a public company. How can remaining shareholders communicate among ourselves; is there a chat room available to us?
Then how would one access it?
Agree with your sentiments. Will this site remain available for us to communicate as MYMX goes private?
MYMX’s two major creditors - Round Enterprises LTD and Eardley Holding, AG - have clauses for over a decade stating that their loans are “secured against all property of the Company”. Does that relate here?
Thanks, that’s good to hear. It seems both MYMX insiders and us shareholders are in flux…it will be very helpful to stay in touch as events unfold.
Would join a class action. Interesting that the SEC quarterly report notes that the reverse split may or may not occur as presented. What is behind the scene seems to be playing out at present.
Hmmm…interesting!
I know that some posters on other stocks have chosen to form private chat spaces from time to time. Does anyone here know how to set that up, either on stocktwits or another chat board, and how to join it? I’m okay with ctlt as a stopgap, but will need something more focused on our status and concerns in the near term.
Me also. Hope all goes well…
How will we communicate after 11/16? I would like to stay informed of shareholder activity regarding MYMX.
True. That seems a moving target still.
Don’t forget MOL - now partnered with Delfin, on their board, and actively pursuing oil resources in the US and globally.
Count me in also.
Thanks again. I will post temporarily on CTLT if this site goes down in the next week - using cast55 alias. Encourage others
to do so until we have a private site organized.
Thanks again for your thoughts, that clearly reflect what many shareholders are feeling right now. I do not know how to setup a chat room, but that seems what we will need to pursue a response to these MYMX decisions after the site is removed from the OTC. I agree that many of us may want to consider options to challenge this situation. We will sign up if you, or another concerned public shareholder, posts a link to enable our discussion to proceed in private once the stock is delisted.
Nor do any of us shareholders appear to have access to the real story behind any of that. But there are hints…
* MYMX hired 2 companies for 7 months to look into the value of MYMX. No findings were reported in SEC documents. What did they do?
* Their financial advisors, Rock Creek Advisors, never even posted the MYMX purchase opportunity on their own company website. How did they earn their keep?
* MYMX is clawing back 2 BH patents, awaiting release of Ruth Ruprecht’s delayed NIH HIV trial results, silent about their covid and other research. These are timely factors in any potential business transaction, but useless to the longterm shareholders who will see their investment into this research agenda diluted…by 2000%.
* Twice in recent SEC filings MYMX warned that a shareholder class action lawsuit would divert their attention from selling the company and thus harm their business. But their “business” instead appears to have been structuring a way to go private and shaft the public shareholders.
* MYMX repeatedly notes that they are “winding down” their company. Given the huge number of shares purchased in recent weeks for this sub-penny stock, that does not appear to reflect their real intent. It seems more like a “going private” path that will remove public shareholders and escape public (SEC) reporting requirements.
Great to hear from you, Llama! Am glad you exited prior to this, and really appreciate your support as remaining shareholders try to parse what is happening and how to respond.
Over the past months there have been days (like today) when multiple millions of shares changed hands in a now sub-penny stock. I wondered at the many identical purchases (ending in 1,999,999)…now it seems clear those were insiders privy to the split vote, and getting their hands on the shares that will be taken from us in just a few weeks.
Another oddity is the stall in publication of the HIV research results. What do those findings reveal? What are implications for the value of the MYMX-patented virosomes used? How might that play into this sudden desire to “go private”?
And finally, why did MYMX management advise shareholders in a public filing not to initiate legal action against the company while they were “trying to sell the company”, when in reality they were focused on a plan to go private and eliminate most of us. What will the SEC have to say about that ?
Again, glad you are out of the fray, and truly appreciate your knowledge and commentary on what is transpiring.
I agree with these sentiments, and suggest that the remaining shareholders create a private online chat room for those who wish to explore our options.
We were asked by MYMX management months ago not to take any legal action, as they were focused on selling the company. However, that clearly was not full disclosure…they were also planning this option. If what they are doing is illegal, we have every right to respond.
Thanks very much for the support, Phosphene. I know that you are well versed in this, and wish you the best in negotiating the difficult decisions currently on the table. Longtime holders will lose a major portion of our investment in the short term, and if we continue to support MYMX it will be with significantly less access to company information in the future.
I did and still do believe that the patents held and the research MYMX engages in remain invaluable to the biotech field. My inclination is to remain a shareholder. But as the company goes private we have no voice - how will we glean information about their work? We don’t know where their new office is, will have no access to regularly scheduled filings, and decisions
affecting investor shares will be solely determined by insiders.
Would there be ways to share information among ourselves going forward? If MYMX is subsequently sold, would we be compensated equitably?
Am reading the new MYMX filings now - thanks, AhsokaXC - and would like to hear others’ thoughts on this development. The timing of this, on the cusp of Dr. Ruprecht’s report on the NIH HIV research project, seems perhaps relevant.
Thank you for these very important updates,Templar. I went to the SEC website yesterday, but find no new filings for MYMX. They no longer trade on the U.S. stock market, and we do not know their new address. They have not yet communicated directly with shareholders, and I am not sure when they plan to do so.
This is obviously not the news we hoped for. The reverse split acknowledges management’s responsibility to shareholders. We are still waiting the results of important research that they are involved in. Since they are going private, we need to know what our shares are worth…I assume that information will be in the next filings.
Do we as shareholders have a plan moving forward amid these major changes?
Thanks yet again for your timely updates, Phosphene. Rapid turnaround on patent application, top researchers working with MYMX, critical need vaccine development. And this patent approval comes AFTER management put this company on the market…!
I view that as a definite win for shareholders. We remain part of any deal that MYMX makes. They clearly are negotiating to receive value for decades of leadership, research, patents and collaborations in virosome development and its application to vaccines for major illnesses. We wait, and support their efforts with our loyalty.
Thanks again for yet more useful dd! Since we are connecting dots, here is a dotted line of thought. Keeping in mind recent news that the estimated cost for LNGs may have quadrupled this year; given that MOL has 4 current LNG build contracts locked in at the former price; and if the Delfin team is able to convert ships from LNG to FLNG at streamlined cost, there may be a deal in the making…
…and a repeatedly hinted-at FID in Delfin’s near future.
See Phosphene’s message from yesterday; the published article is cited in it’s entirety at the end (just click on it)
Great timing of this publication - thanks for sharing! I have wondered about MYMX’ silence regarding their COVID vaccine efforts…this affirms progress in another strand of that research.
I’m assured by the most recent 10Q that they are in talks with various interested party(s) regarding potential sale/merger of some or all of the company’s patents, products and IP. Given the experts they recently brought aboard to assist with this effort, I doubt that they are “limping along”, but rather making serious efforts to secure a viable future for MYMX. The next several months will tell…
…and in the Q1 2023 report released last month, PCI Biotech indicates that fimaVacc collaborations with MDimmune, OLiX & IMV continue; was MYMX the only collaboration that ended?
…curious that PCI Biotech filed that patent application at the time the collaboration was dissolved…
Per the PCI Biotech 2022 Annual Report filed on 27 April 2023, they had an active collaborative strategy in 2022 for fimaVacc, including partners MDimure, OLiX Pharmaceuticals, IMV, and MYMX. The collaboration was to explore synergies between their proprietary technologies, with potential expansion of the partnerships. In August of 2022 they made the decision not to pursue a PCI Biotech-sponsored fimaVACC Phase 2 study to explore technological synergies for cancer therapy, and subsequently disbanded that collaboration during the latter part of 2022. Full cost reduction of this program occurred in Q1 of 2023.
That’s strange, since Rock Creek are financial advisors to MYMX. Seems they don’t want to be “open to the public”in marketing themselves. I would expect they have interest from companies they do/have worked with…so much potential, early stage positive results, valuable patents. If they merge/RM we will be involved somehow; if they go private what happens to shareholders?
Any news/opinion re. Yahoo stocktwits rumor of potential MYMX offer on the table?
Thanks very much for these postings of latest 10Q news. Another site suggests there is an offer on the table. Situation appears very fluid indeed.
Very interesting background to this major undertaking! Thanks for sharing; it certainly attests to perseverance of the private Delfin group over the past decade to get this massive project up and running. It appears that we are now on the cusp of that: approvals secured, major contracts signed, FID in the wings, and berths for FLNG vessel construction reserved. Recent history makes the need for LNG pressing for many countries. The timing is right, and TGLO remains a critical asset in this process - a potential vehicle for Delfin to access massive collateral (e.g., stocks) needed to become operational over the next several years. We are aboard and ready!
I actually think this was the most detailed and positive 10K I’ve read in the 8 years I’ve been invested here. MYMX has made real progress in vaccines for allergies, covid and HIV over the past few years, and has a strong portfolio of solid patents. Rather than lamenting their shortcomings, they are finally touting their accomplishments in the service of marketing themselves to potential buyers. I thank the company for being more transparent with us, and will be holding for news.